Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer

2007755 citationsJournal Article

Authors

Stephen A. Cannistra · Moffitt Cancer Center

Ursula A. Matulonis · Sidney Kimmel Cancer Center

Richard T. Penson · Dana-Farber Cancer Institute

Julie Hambleton · Moffitt Cancer Center

Jakob Dupont · Moffitt Cancer Center

Howard Mackey · Sidney Kimmel Cancer Center

Jeffrey A. Douglas

Abstract

Bevacizumab has single-agent activity in patients with platinum-resistant EOC or PSC. A higher than expected incidence of GIP was noted in these heavily pretreated patients.

Topics & Keywords

Ovarian cancer diagnosis and treatment Intraperitoneal and Appendiceal Malignancies Renal cell carcinoma treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 25, Issue 33, pp. 5180-5186

DOI: 10.1200/jco.2007.12.0782

Field-Weighted Citation Impact: 71.64